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Background: Approximately 90,000 Canadians use opioids each year, many of whom experience health and social
problems that affect the individual user, families, communities and the health care system. For those who wish to
reduce or stop their opioid use, methadone maintenance therapy (MMT) is effective and supporting evidence is
well-documented. However, access and availability to MMT is often inconsistent, with greater inequity outside of
urban settings. Involving community based primary-care physicians in the delivery of MMT could serve to expand
capacity and accessibility of MMT programs. Little is known, however, about the extent to which MMT, particularly
office-based delivery, is acceptable to physicians. The aim of this study is to survey physicians about their attitudes
towards MMT, particularly office-based delivery, and the perceived barriers and facilitators to MMT delivery.
Methods: In May 2008, facilitated by the College of Physicians and Surgeons of Nova Scotia, a cross-sectional,
e-mail survey of 950 primary-care physicians practicing in Nova Scotia, Canada was administered via the OPINIO
on-line survey software, to assess the acceptability of office-based MMT. Logistic regressions, adjusted for physician
sociodemographic characteristics, were used to examine the association between physicians’ willingness to
participate in office-based MMT, and a series of measures capturing physician attitudes and knowledge about
treatment approaches, opioid use, and methadone, as well as perceived barriers to MMT.
Results: Overall, 19.8% of primary-care physicians responded to the survey, with 56% who indicated that they
would be willing to be involved in MMT under current or similar circumstances; however, willingness was
associated with numerous attitudinal and systemic factors. The barriers to involvement in MMT that were frequently
cited included a lack of training or experience in MMT, lack of support services, and potential challenges of working
with an MMT patient population.
Conclusions: Study findings provide valuable information to help facilitate greater involvement of primary-care
physicians in MMT, while highlighting concerns around administration, support, and training. Even limited uptake
by primary-care physicians would greatly enhance MMT access in Nova Scotia, particularly for methadone clients
located in rural communities. These findings are applicable broadly, to any jurisdictions where office-based MMT is
not currently available.
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The impact of opioid use on Canadians is substantial;
the economic costs are high and health risks include
transmission of blood borne disease, overdose, prema-
ture mortality and a host of other conditions [1-5].
Methadone, a long-acting synthetic opioid agonist, is an
effective treatment for opioid dependence, and evidence
of positive health outcomes for opioid users and their
surrounding communities is well-documented [6-13].
However, methadone maintenance therapy (MMT)
remains controversial and underutilized, and the degree
to which MMT policies and programs are available, ac-
cessible, and adopted varies significantly between geo-
graphical and professional settings and facilities across
the country.
A recent spate of prescription opioid drug-related
deaths in Nova Scotia has received attention from the
Minister of Health and a promise for more MMT spots
[14]. Data on 431 drug-related deaths in Nova Scotia
from Jan 2009 to Dec 2011 points to the heavy involve-
ment of prescription opioids. Hydromorphone contribu-
ted to 19% of drug-related deaths, morphine 11%, and
oxycondone 9%, compared with only one heroin-related
death (C. Davidson, personal communication, May 22,
2012). Data on opioid treatment show a similar pattern.
Treatment data from 2009–2010 indicate that 1272
Nova Scotians received treatment for opiate dependence,
fewer than 10 of which involved heroin [15]. These
numbers represent a substantial increase from just
10 years earlier [1].
Few primary-care physicians (general practitioners and
family physicians) in Nova Scotia offer MMT and the
capacity of community-based programs is limited, par-
ticularly outside of larger urban settings. As a result,
many opioid-dependent persons who could benefit from
MMT go untreated. Office-based MMT delivery has
been suggested as an alternative to traditional specialized
outpatient clinics that may aid in improving accessibility,
reducing stigma and addressing the diverse needs of the
opioid-using population [16-22]. Clinic-based delivery
limits access to users who lack adequate transportation
or for those who live a great distance from the clinic,
disrupting normal daily routines as users must spend a
great deal of time and resources just to obtain MMT.
Office-based MMT delivery through a primary-care
physician alleviates many of these issues, particularly if
physicians are spread optimally around urban and rural
settings in a given region.
Methadone maintenance is the main pharmacothera-
peutic treatment for opioid dependence offered in
Canada, although buprenorphine and other therapeutics
treatments are available [23]. The delivery of methadone
in Canada, including physician authorization, certifica-
tion and MMT training, is regulated at the provinciallevel. As such, there is tremendous variability in avail-
ability and access across provinces. While the integration
of MMT into primary care settings is encouraged, most
MMT is still delivered through specialized clinics [24].
Office-based methadone maintenance delivered by
primary-care physicians has been implemented in parts
of Canada [20,25,26], and evidence points to its feasibil-
ity and effectiveness [11,21,27], including its cost effect-
iveness [28]. Treatment may be integrated into a
dynamic community-based model of care [20,29] or
patients, who have been stabilized on methadone, may
be referred to a primary-care physician for continued
but less intensive care [19,29].
The success of such a model is dependent in large part
on the willingness of primary care physicians to deliver
MMT as part of their office-based practice. As identified
in Health Canada’s [24] “Best Practices” document for
MMT, program acceptability is essential to improving
MMT access and delivery. While office-based MMT de-
livery has expanded in Ontario and British Columbia,
acceptability and, in turn, access in other parts of
Canada remains limited. This study seeks to clarify the
acceptability of MMT delivery among primary-care phy-
sicians in Nova Scotia, to determine their willingness to
participate in office-based MMT, and to identify the bar-
riers to participation in MMT delivery. The degree to
which MMT practice is espoused by physicians sheds
light on the potential for office-based MMT as a poten-
tial solution to access, while the perceived barriers to
office-based delivery of MMT identifies unmet needs
and social and political barriers. We address here the
factors that may influence effective implementation of
MMT, and highlight areas for improved treatment
accessibility.
Methods
Study design and participants
We conducted a cross-sectional survey of primary-care
physicians licensed in Nova Scotia, the objective of
which was to assess acceptability of office-based MMT.
The survey, developed in conjunction with the Nova
Scotia College of Physicians and Surgeons, and adminis-
tered by the College via e-mail in May 2008, was sent to
950 primary-care physicians including family physicians,
general practitioners, and emergency room physicians.
The names and addresses of the individual physicians
were not provided to the research team, and all
responses were anonymous.
Efforts were made to keep the survey as concise and effi-
cient as possible [30]. The survey asked 29 questions on a
range of topics around MMT knowledge, attitudes to-
wards drug use, and perceived barriers, and took, on aver-
age, 20 minutes to complete. Content validity of the
survey was assessed by creating a matrix that represented
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main had adequate coverage [31]. In order to validate the
scale for use in the Canadian context, experts in the field
of methadone maintenance were asked to assess face and
content validity for questions regarding barriers and facili-
tators to MMT delivery. Fifteen individuals, purposively
sampled from the study population, participated in a pre-
test of the survey; minor changes were made based on
their feedback.
Approval for this study was obtained from the Office of
Human Research Ethics at Dalhousie University, and from
the Nova Scotia College of Physicians and Surgeons.
Data collection
OPINIO on-line survey software (Version 6.4.4, Object-
Planet, Inc: Oslo, Norway) was used to administer the
survey. A link to the survey was e-mailed by the College
of Physicians and Surgeons of Nova Scotia to all
primary-care physicians with an e-mail address on rec-
ord. The survey was preceded by a letter of explanation
that also served as a letter of consent and highlighted
the potential of the results to which participants would
be contributing. Individuals were e-mailed first on
Thursday May 15th, 2008; a follow-up reminder was
sent ten days later.
A total of 189 responses were received, 130 of which
were complete. This resulted in a response rate of 19.8%
overall and 13.7% for complete responses. However, it is
important to note that the true denominator with which
to calculate the response may be lower as the e-mail list
may include individuals that do not qualify to complete
the survey (e.g. retired physicians still registered with the
College). Nonetheless, the low response rate likely intro-
duces response bias to the survey, as physicians with
stronger opinions, knowledge, and experiences with
MMT are more likely to have responded. Previous sur-
veys conducted by the College of Physicians and
Surgeons of Nova Scotia have had a response rate
between 17 and 30% (personal communication).
Physicians over 50 years of age represented the largest
proportion of respondents (35%), followed by those 41–
50 (31%), 31–40 (23%), and those under 30 (11%). Just
over half of participants were male (54%). Almost half of
the respondents practiced in communities of over
50,000 population (Halifax and Sydney), while 40% prac-
ticed in communities of 5,000-50,000 people, and 13%
practiced in communities of under 5,000 people. Practice
setting varied with 20% involved in a solo private prac-
tice, 38% in a group private practice, and 41% in some
other type of practice.
Only 14 participants (7%) had ever held a license to pro-
vide methadone for opioid dependence. The majority of
participants (almost three quarters) had minimal training
in addiction medicine or methadone maintenance,primarily workshops or lectures on addiction medicine
and/or self-study. A small proportion had attended a
course in addiction medicine and/or methadone
maintenance.Outcome measures
The primary outcome of interest was ‘acceptability of
office-based MMT’, as measured by willingness to par-
ticipate in office-based MMT. Participants were asked to
indicate one statement that most accurately reflected
their current willingness to prescribe methadone and
manage opioid dependent patients in their office-based
practice. The statements were: “I would potentially be
willing to provide office-based methadone maintenance
treatment under current circumstances”; “I would poten-
tially be willing to provide office-based methadone main-
tenance treatment under different circumstances”; and “I
would not be willing to provide office-based methadone
maintenance treatment under any circumstances”.
Responses were dichotomized into those willing (either
current or different circumstance) to provide MMT and
those unwilling.Explanatory measures
Acceptability of office-based MMT was measured in re-
lation to a number of independent variables thought to
be associated with willingness. These included: a) atti-
tudes towards treatment philosophy (commitment to
abstinence-oriented approaches to treatment versus
maintenance-oriented approaches), b) attitudes towards
opioid users and opioid dependence, c) knowledge of the
risks and benefits of methadone maintenance treatment
(including office-based MMT) and d) perceived barriers
to office-based MMT.
Attitudes towards treatment were measured with the
Abstinence Orientation scale (see Table 1, Column 1),
which consists of 14 items that reflect two dimensions
of support for abstinence oriented maintenance; an ‘ab-
stinence goal’ measuring a commitment to the goal of
abstinence and ‘compliance’, measuring support for the
use of disciplinary sanctions to enforce compliance with
program rules [32]. The Disapproval of Drug Use scale
(Table 1, Column 2) consists of six items that are con-
cerned with attitudes towards punitive treatment of
illicit drug use. All items are attached to a Likert scale
responses are scaled between 1 (strongly agree) and 5
(strongly disagree). The final score is reflective of the
summed score for all items divided by the total number
of items (14 and 6, respectively), thus the range of final
scores for each item is between 1 and 5. These scales
were developed and validated in Australia, though nei-
ther has been used previously in Canada. However, tests
of the internal reliability of scale items (Abstinence
Table 1 Items in the Abstinence Orientation, Disapproval of Drug Use, and Knowledge of MMT scales
Abstinence Orientation Scale Disapproval of Drug Use Scale Knowledge of the risks and benefits of MMT
1) Methadone maintenance patients who
continue to use illicit opiates should have
their dose of methadone reduced.
1) Marijuana should be legalized. 1) Methadone, in a stable dose as part
of a maintenance regime, blocks the
euphoric effects of heroin and prescription opioids.
2) Maintenance patients who ignore
repeated warning to stop using illicit
opiates should be gradually withdrawn
off methadone.
2) Modern society is too tolerant
toward drug addicts.
2) Withdrawing from methadone ‘cold
turkey’ is definitely worse than withdrawing
from heroin.
3) No limits should be set on the duration of
methadone maintenance.
3) Drug addiction is a vice. 3) Methadone maintenance can cause
chronic constipation.
4) Methadone should be gradually withdrawn
once a maintenance patient has ceased using
illicit opiates.
4) Marijuana use among
teenagers can be
healthy experimentation.
4) Methadone Maintenance can cause
disturbance of sexual function.
5) Methadone services should be expanded
so that all narcotic addicts who want
methadone maintenance can receive it.
5) Drug addiction is a menace
to society.
5) Methadone maintenance can cause kidney
damage.
6) Methadone maintenance patients who
continue to abuse non-opioid drugs
(e.g. benzodiazepines) should have
their dose of methadone reduced.
6) Persons convicted of the sale of
illicit drugs should not be eligible
for parole.
6) Methadone maintenance can cause liver
damage.
7) Abstinence from all opioids
(including methadone) should be the
principal goal of methadone maintenance.
7) To the unborn child, methadone is more
dangerous than heroin.
8) Left to themselves, most methadone
patients would stay on methadone for life.
8) Methadone given in a stable dose as
part of a maintenance regime significantly
interferes with the ability to dive a car.
9) Maintenance patients should only be
given enough methadone to prevent
the onset of withdrawals.
9) Methadone maintenance reduces
addicts’ criminal activities.
10) It is unethical to maintain addicts
on methadone indefinitely.
10) Methadone maintenance decreases
addicts’ risk of dying.
11) The clinician’s principal role is to prepare
methadone maintenance patients for
drug-free living.
11) Methadone maintenance
reduces addicts’ consumption of illicit opiates.
12) It is unethical to deny a narcotic addict
methadone maintenance.
12) Methadone maintenance
increases the severity of preexisting depression.
13) Confrontation is necessary in the
treatment of drug addicts.
13) Methadone maintenance
reduces the risk of transmission blood
borne diseases.
14) The clinician should encourage patients
to remain in methadone maintenance
for at least three to four years.
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α= 0.63) were moderate to strong [30].
Knowledge of the risks and benefits of MMT were
measured with a Knowledge scale (Table 1, Column 3)
consisting of 12 statements regarding MMT. The ori-
ginal scale contained 13 items, however one question
was deemed to be ambiguous. Responses to each state-
ment were either true, false, or uncertain, with one point
awarded for correct answers, one point subtracted for
incorrect answers, and no points were given for uncer-
tain responses [33], and thus scores on the knowledge
could range from −12 to +12.Finally, perceived barriers to office-based MMT were
assessed using the Barriers to Methadone Prescribing
scale, a tool developed for this study. The Barriers to
Methadone Prescribing scale was comprised of 16 ques-
tions drawn from the purposively sampled group of phy-
sicians and previous research on barriers to MMT
among physicians [26,34-40]. These questions tapped
into a range of common barriers to treatment that have
been previously identified, such as belief in the effective-
ness of methadone, availability of support from specia-
lists, availability of resources, and concerns about this
patient population (See Table 1). As above, items were
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agree), where each item was given a score between 1
and 5.
Given that this was a previously unvalidated scale, and
due to the high correlation between items, a principal
components analysis was performed. Rather than elimin-
ating some of the variables from the analysis, and thus
reducing the amount of variance that can be explained,
principal components analysis made it possible to create
principal component scores, which are uncorrelated lin-
ear combinations of weighted observed variables, and
therefore explain as much variance as possible. The prin-
cipal component analysis found that the 16 items loaded
onto three distinct factors (see Table 2 for factors/load-
ings), representing concerns about: 1) risks associated
with MMT delivery (α= 0.80); 2) training and supportTable 2 Principal components analysis of items in
Barriers to Methadone Prescribing Scale
Factor names and items Factor Loadings
Risks associated with MMT delivery Factor 1 Factor 2 Factor 3
1. Don’t want it known that I have
a methadone license
0.74* 0.27 0.19
2. It would shift my practice
too much to patients
with opioid dependence
0.81* 0.13 0.02
3. Afraid of patient diversion of
methadone
0.75* 0 −0.05
4. Fear of becoming
involved with surveillance
0.58* 0.13 0.47
5. Am generally uncomfortable
managing patients with opioid
dependence
0.55* 0.01 0.33
6. Difficult patient population 0.57* 0.17 0.15
Training and support issues
7. Not enough reimbursement 0.13 0.46* 0.32




9. Not enough political commitment 0.15 0.54* 0.31
10. Not enough support services
(e.g. drug screening, addiction
counseling services)
0.03 0.62* 0.19
11. Too much paperwork 0.27 0.80* 0.04
Too much time involved 0.37 0.76* −0.13
Little or no experience, training
or education in the use of methadone
for opioid dependence
0.01 0.51* −0.10
Resistance from external sources
Community resistance 0.13 0.03 0.90*
Staff resistance 0.17 0.05 0.86*
Extensive regulations 0.14 0.34 0.71*
*Loading used for interpretation of factors.issues (α= 0.75); and 3) resistance from external sources
(α= 0.82).
Additionally, we included a number of variables re-
flective of physician’s sociodemographic (age, gender)
profile, location of training (North America or other),
practice setting (solo, group private, clinic, other), size of
the community in which they practice (under 5,000,
5,000 to 50,000, over 50,000 people), whether they
received formal training in addiction medicine, and
whether they are licensed to prescribe methadone.
Open-end questions were also included in each section
of the survey to allow physicians to offer additional
responses not captured in the close-ended questions or
to offer insight and opinions on the subject matter.
Statistical analysis
Analysis followed two stages. First, descriptive statistics
were used to summarize our outcome and main ex-
planatory variables. Second, the association between
willingness to prescribe methadone (measured dichot-
omously) and knowledge of the risks and benefits of
MMT, attitudes to illicit drug use (DDU), attitudes to
MMT (AO), and the three factors in the perceived bar-
riers to MMT delivery, was examined with logistic re-
gression. Unadjusted associations with other covariates
(age, gender, location of training, community size, addic-
tions medicine training) were also obtained. Employing a
likelihood ratio test, and a p value threshold of 0.25, cov-
ariates that did not contribute to the model were elimi-
nated from a final adjusted logistic model. Key
explanatory measures were retained in all models. Logis-
tic models present odds ratios and 95% confidence inter-
vals, and include only those 130 physicians who
answered all questions in the survey. All data analysis
was performed using SAS statistical software (SAS Insti-
tute Inc., Cary, NC, USA. 2008, Version 9.1).
Results
Overall, sixty-eight individuals (57%) were ‘willing’ to
prescribe methadone and 51 (43%), were ‘unwilling’. In
terms of explanatory measures, both the mean score on
the Disapproval of Drug Use (DDU) scale (mean 3.25,
SD 0.69) and the Abstinence Orientation (AO) scale
(mean 3.00, SD 0.54) score were above 3 (scored out of
a possible 5 points), with higher scores indicating a ten-
dency towards disapproval of illicit drug use and an
orientation towards abstinence. The mean score on the
Knowledge scale was low (6.25 out of a possible 12
points, SD 3.50), demonstrating that additional training
in the risks and benefits of methadone maintenance
would likely be beneficial.
The correlation between the AO scale and the DDU
scale was 0.51 (p=<0.0001) indicating that a higher
score on the AO scale is associated with a higher score
Table 3 Logistic regression of willingness to prescribe
methadone on scales and other covariates (n =119)
Unadjusted Adjusted
Explanatory Measures OR 95% CI OR 95% CI
Age (referent = over 51)
Under 30 4.29 0.82 22.31
31–40 1.13 0.41 3.09
41–50 1.32 0.56 3.13
Sex (referent =male)
Female 3.04 1.41 6.56 3.75 1.55 9.01
Community Size (referent = over
50,000)
Under 5,000 0.66 0.22 2.00
5,000–50,000 0.53 0.24 1.18
Location of Graduation
(referent =Other)
North America 2.52 0.85 7.47
Type of Practice (referent =Other)
Group or solo private practice 0.83 0.40 1.75
Knowledge Test score 1.09 0.73 1.61 1.11 0.69 1.78
Education in Addiction Medicine 1.86 0.88 3.93
Disapproval of Drug Use Scale
factor score
0.61 0.37 0.99 0.60 0.32 1.13
Abstinence Orientation Scale
factor score
0.59 0.38 0.93 0.83 0.46 1.48
Barriers to Methadone Prescribing
Scale
Risks associated with MMT delivery
factor
0.69 0.46 1.03 0.77 0.49 1.22
Training and support issues factor 1.59 1.04 2.43 1.63 1.04 2.54
Resistance from external sources
factor
0.98 0.65 1.46 0.95 0.61 1.47
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scale was associated with lower scores on the AO and
DDU scales. The correlation between the AO scale score
and the Knowledge scale score was −0.34 (p=<0.0001)
while the correlation between the DDU scale score and
the Knowledge scale was −0.186 (p= 0.025).
As described above, while principal components ana-
lysis of items in the Barriers to Methadone Prescribing
scale revealed three distinct factors, it is important to
note specific results for some of the items in the scale.
Perceived barriers for which there was a high level of
agreement included perceptions of a ‘lack of support ser-
vices’ (66% agreement), having ‘little or no experience’
with the population (69% agreement), and the belief that
methadone users were a ‘difficult patient population’
(69%). Primary-care physicians disagreed with the per-
ception that methadone is not effective (66%), and that
they had a ‘fear of surveillance’ (40%), or that there was
‘community resistance’ (44%) and ‘resistance from other
staff ’ (44% overall). The mean score for the factors was
calculated by adding the individual item scores, dividing
by the number of items included in that factor, and by
the number of responses. This resulted in a standardized
score out of 5 for each factor, a higher score signifying
higher level of agreement. The mean score for ‘training
and support’ was highest, with a mean score of 3.37. The
mean score for ‘risks’ was 3.22, and the mean score for
‘external resistance’ was lowest at 2.80.
Unadjusted results are summarized in Table 3. It was
found that being female (OR= 3.04, 95%C.I. 1.41-6.56)
and ‘training and support’ on the Barriers to Methadone
Prescribing scale (OR= 1.59, 95%C.I. 1.04–2.43) were
significantly positively associated with willingness to pre-
scribe methadone. Conversely, a significant negative as-
sociation was observed between willingness to prescribe,
the DDU scale (OR 0.61, 95%C.I. 0.37–0.99), and the
AO scale (OR 0.59, 95%C.I. 0.38–0.93). The direction of
the association indicates that greater agreement with
these items is associated a lower willingness to prescribe
methadone. All remaining explanatory measures were
not significantly associated with willingness to prescribe
methadone.
An adjusted model found being female (OR=3.75,
95%C.I. 1.55–9.01) and the ‘training and support’ factor
of the Barriers to Methadone Prescribing scale
(OR= 1.63, 95%C.I. 1.04–2.54) were the only explana-
tory measures significantly associated with willingness to
prescribe methadone.
Physicians were also given the opportunity to provide
open-ended comments. While some physicians
expressed comfort and skill with working with the popu-
lation, others expressed frustration at the current state
of MMT delivery. For example one physician stated “In
general I strongly support changes to the existingregulations to make methadone more easily and widely
available. The existing paranoid treatment of methadone
as a ‘special’ drug, requiring specific licensing, has no
basis in science or rationality.” This sentiment was
echoed by another physician: “Once the state legalizes
currently illegal drugs, and gets out of the way of decent
physicians trying to help their patients, then I would be
willing to offer a methadone treatment service, and not
before. Getting on board now simply aids and abets the
status quo”.
Issues of administrative support and training were also
reflected upon in responses to open-ended questions in
the survey. One physician working in the context of
Correctional Services commented on the lack of suffi-
cient community resources to sustain individuals once
they have returned to their communities and noted that
women especially have a problem finding services near
their families or halfway houses in communities in
which methadone services are available. Some physicians
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sing concern about the degree of support they would re-
ceive should complaints be made. Others cited concern
about systemic support and remuneration. Others spoke
of broader prevention and improved population health,
noting the need for “upstream” investment in “strategies
that support families and community, to improve early
childhood development, deal with learning disabilities,
etc., and so work to prevent the difficulties that lead to
involvement with addiction”.
Discussion
We found a considerable level of willingness (56%) to
participate in methadone maintenance treatment among
a sample 189 (response rate of 19.8%) primary-care
physicians in Nova Scotia. Of these physicians, only 15%
indicated that they would be willing to participate in
MMT under current circumstances, while 44% indicated
that they would be unwilling to participate in MMT
under any circumstances. To contextualize findings fur-
ther we employed a series of scales to examine primary-
care physicians’ attitudes towards illicit drug use and
abstinence orientation, and their knowledge of MMT.
Overall, the mean Disapproval of Drug Use scale score
indicated considerable disapproval of illicit drug use
among primary-care physicians, and those physicians
with higher disapproval scores were significantly less
willing to prescribe methadone. Similarly, a high mean
score was found on the Abstinence Orientation scale,
demonstrating that primary-care physicians prefer
abstinence-based treatment for substance users rather
than maintenance (harm reduction) approaches. A high
abstinence orientation was also negatively associated
with a willingness to prescribe methadone. We found,
overall, that primary-care physicians had limited know-
ledge of methadone maintenance therapy; however
knowledge was not associated with willingness to pre-
scribe methadone. We identified numerous barriers to
office-based methadone maintenance treatment, and of
particular significance were issues related to training and
support.
Considered along with low knowledge levels, a higher
orientation to abstinence-based therapies may indicate,
among other things, that best practices in MMT are
poorly disseminated and not reaching physicians, or re-
flective of limited addictions training in medical educa-
tion. Of course, it may simply be that physicians’ less
than positive attitudes and values about MMT and illicit
opioid use holds influence on their opinions about clin-
ical decisions [41]. Enhancements to both undergraduate
medical training and continuing medical education may
represent reasonable approaches to shaping clinical
practice in this area, particularly since there is a willing-
ness to become educated: forty percent of primary-carephysicians surveyed indicated that they would be willing
to be trained in MMT, preferably by academic detailing,
group seminars, regular symposia and time spent with a
mentor. A study from the United Kingdom found that
the publication of clear and concise best practice guide-
lines for methadone and buprenorphine prescribing
coincided with a doubling of methadone prescriptions
and considerable improvements on a number of clinical
decision-making outcome measures [42].
Potential barriers to primary-care physician participa-
tion in the delivery of office-based MMT were also
examined. The barriers most frequently identified in the
survey addressed a lack of experience or training, the
difficult nature of the patient population, a lack of sup-
port services, and the need for more interaction with
other methadone providers, all of which have been pre-
viously identified [34-36]. In general, the administrative
barriers highlighted in this study are systemic and are
not specific to methadone prescribing, as highlighted by
the 2007 National Physician Survey conducted by the
College of Family Physicians of Canada [43].
Our study was cross-sectional and the response rate
was limited, making it impossible to draw overarching
conclusions about the willingness of primary-care physi-
cians to participate in MMT at the population level.
Non-response was analyzed by comparing the group of
responders with the population of primary-care
physicians in Nova Scotia, drawn from the Office of
Continuing Medical Education (CME) at Dalhousie Uni-
versity, across a number of demographic characteristics.
Results of this comparison indicate a comparable ratio
of female to male physicians, though a strong divergence
in age was observed. Survey respondents were consider-
ably younger than the population of Nova Scotia
primary-care physicians. Some of this discrepancy may
be explained by the fact that current residents or recent
graduates are not included in the list provided by CME,
while they were included in the distribution of the sur-
vey. Likewise, retirees may not have received the survey
or may have chosen not to complete the survey, but re-
main included in the CME list. Additionally, a larger
proportion of survey respondents practiced in communi-
ties with a population 50,000 or more when compared
to all primary-care physicians in Nova Scotia. This dis-
crepancy may be explained by the perceived salience of
this issue in communities of different sizes. Those from
small communities may feel that opioid dependence is
not a major issue in their communities and choose not
to participate, while physicians from larger communities
may perceive opioid dependence to be an issue of
greater importance.
One additional limitation relates to the wording of ques-
tions on future prescribing intention. These questions ex-
cessively qualify the conditions under which a physician
Dooley et al. Harm Reduction Journal 2012, 9:20 Page 8 of 9
http://www.harmreductionjournal.com/content/9/1/20would be willing to prescribe MMT; as such, there is a po-
tential uncertainty created by this question that may have
biased results about physicians’ true intentions. Despite
these concerns,, many of the study findings are valuable in
that they offer insight and direction for medical education,
and for the development of provincial strategies to re-
spond to the limited access to MMT treatment in Nova
Scotia and other jurisdictions. Overall, 68 physicians indi-
cated their willingness to prescribe MMT under the right
circumstances. If even half of these physicians could be-
come active prescribers, access problems could be sub-
stantially reduced or eliminated.
Conclusion
In conclusion, methadone maintenance treatment is a
health service that can have a dramatic impact on indivi-
duals and their communities, but one that has traditionally
not received full acceptance by the medical community.
This is the image that was conveyed by primary-care phy-
sicians who responded to our survey. In general, our
respondents’ attitudes leaned more towards disapproval of
drug use and orientation to abstinence rather than main-
tenance therapy, both of which were associated with lower
willingness to prescribe methadone. Overall, however, we
found physicians willing to be educated and involved in
MMT – though not necessarily given current political and
administrative structures, poor resources, and lack of sup-
ports. Continuing Medical Education programs in MMT
and clear, concise provincial guidelines on the administra-
tion of MMT may serve to support the provision of these
services. The barriers highlighted by our respondents
identify areas not only of systemic improvement needed,
but also areas where more information and experience
may serve to allay fears about risks associated with MMT
provision. This must be aimed not only at current
primary-care physicians, but also at the undergraduate
medical education curriculum in order to improve aware-
ness and understanding of addict populations and appro-
priate treatments.
We have also highlighted the potential of this mode of
MMT delivery to improve MMTcapacity and accessibility,
such that primary-care physicians may be willing to be
engaged in office-based MMT under appropriate condi-
tions. Primary-care physicians have a role to play in the
delivery of MMT but, based on our results, there are con-
siderable perceived and real barriers standing in the way
of realizing our full potential in implementing this much-
needed service. The recent and tragic prescription opioid
abuse-related deaths in Nova Scotia, and other areas,
reinforce the salience of this issue and the timeliness of
action.
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